Baliunas, Dolly
Ivanova, Anna
Tanzini, Elise
Dragonetti, Rosa
Selby, Peter http://orcid.org/0000-0001-5401-2996
Article History
Received: 27 August 2019
Accepted: 31 March 2020
First Online: 21 May 2020
Compliance with ethical standards
: This study was approved by the Research Ethics Board of the Centre for Addiction and Mental Health (CAMH). Informed consent was obtained from all individual participants prior to collection of any study data.
: Dolly Baliunas and Peter Selby report grants from Pfizer Inc. through the Global Research Awards in Nicotine Dependence (GRAND) program. In the last 5Â years, Peter Selby additionally reports grants from Pfizer Inc./Pfizer Canada, Bhasin Consulting Fund, Shoppers Drug Mart, and Patient-Centered Outcomes Research Institute; has received honoraria for speaking engagements from Pfizer Canada Inc., ABBVie, and Bristol-Myers Squibb; and has also received consulting fees from Pfizer Inc./Pfizer Canada, Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Miller Medical Communications, MedPlan Communications, NVision Insight Group, Inflexxion Inc., Kataka Medical Communications, Sun Life Financial, and Myelin & Associates. Through an open tender process, Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which Peter Selby is the principal investigator or co-investigator. Anna Ivanova, Elise Tanzini, and Rosa Dragonetti declare that they have no conflict of interest.